In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Emergent Biosolutions (EBS), with a price target of $75. The company’s shares closed yesterday at $64.58.
Folkes commented:
“As investors appreciate the durability and revenue potential of Emergent’s portfolio, we expect upward earnings revisions and multiple expansion to drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $75. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA to get to our PT of $75.”
According to TipRanks.com, Folkes is a 2-star analyst with an average return of -0.3% and a 37.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Emergent Biosolutions with a $71.80 average price target.
See today’s analyst top recommended stocks >>
Emergent Biosolutions’ market cap is currently $3.24B and has a P/E ratio of 33.00. The company has a Price to Book ratio of 3.35.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock. Last month, Sue Bailey, a Director at EBS sold 17,717 shares for a total of $1,233,280.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures that address public health and national security threats. It includes Chemical, Biological, Radiological, Nuclear and Explosive or CBRNE threats; as well as emerging infectious diseases.
